Grifols, a global healthcare company and producer of plasma-derived medicines, has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based biomarkers that could indicate a person’s likelihood of developing Parkinson’s disease (PD) many years before clinical diagnosis. The initiative, called “Chronos-PD,” aims to accelerate the discovery of new diagnostic tools as well as the identification and development of novel disease-modifying therapeutic...